linjc16/ctgov huggingface dataset:
Identifying Ultrasonic Diagnostic Characteristics of Cervical Lymphadenopathy: A Retrospective, Multicenter Study

Study Overview
=================
Brief Summary
-----------------
The observed indexes of the four cervical lymph node diseases were identified by informatics methods, and the differences in the diagnosis of the four diseases were evaluated, so as to improve the clinical diagnosis rate and provide a research basis for the ultrasonic evaluation of the surgical indications of cervical lymph node diseases in the future.

Official Title
-----------------
Identifying Ultrasonic Diagnostic Characteristics of Cervical Lymphadenopathy: A Retrospective, Multicenter Study

Conditions
-----------------
Lymph Node Disease, Ultrasound Therapy; Complications

Intervention / Treatment
-----------------
* Diagnostic Test: Ultrasonic image collection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with one of these four diseases Exclusion Criteria: 1. Patients with severe heart and brain diseases and poor coagulation function. 2. Undiagnosed patients are not included in the statistical analysis. 3. Image distortion of CEUS acquisition cannot be analyzed.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cervical lymph nodes tuberculosis<br>The patients with Cervical lymph nodes tuberculosis | Diagnostic Test: Ultrasonic image collection<br>* Ultrasonic image collection,consist of three static images and one dynamic image<br>|
| Cervical lymphoma<br>The patients with | Diagnostic Test: Ultrasonic image collection<br>* Ultrasonic image collection,consist of three static images and one dynamic image<br>|
| Cervical lymph node metastasis<br>The patients with | Diagnostic Test: Ultrasonic image collection<br>* Ultrasonic image collection,consist of three static images and one dynamic image<br>|
| Cervical Reactive hyperplasia<br>The patients with | Diagnostic Test: Ultrasonic image collection<br>* Ultrasonic image collection,consist of three static images and one dynamic image<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cervical lymph nodes tuberculosis | It was identified as cervical lymph node tuberculosis by imaging observation | through study completion, an average of 1 year | 
| Cervical lymphoma | It was identified as cervical lymphoma by imaging observation | through study completion, an average of 1 year | 
| Cervical lymph node metastasis | It was identified as Cervical lymph node metastasis by imaging observation | through study completion, an average of 1 year | 
| Cervical Reactive hyperplasia | It was identified as Cervical Reactive hyperplasia by imaging observation | through study completion, an average of 1 year |
Urinary Circulating Tumor DNA Detection in Non-small Cell Lung Cancer: a Prospective Study

Study Overview
=================
Brief Summary
-----------------
This study will evaluate the feasibility and effectiveness of urinary ctDNA detection and dynamic monitoring during treatment of NSCLC patients prospectively,by collecting and detecting tumor tissues, peripheral blood samples and urine samples of NSCLC patients.

Detailed Description
-----------------
Liquid biopsy, specifically through the assessment of circulating tumor DNA(ctDNA) from peripheral blood, has shown great promise in lung cancer diagnosis and therapeutic monitoring. Urinary samples are completely non-invasive and easily obtainable compared to blood and tissue extraction. To date, only a limited number of published studies have examined the feasibility of ctDNA detection from urine. This study will collect tumor tissues, pretreatment peripheral blood samples and urine samples from different TNM stages of NSCLC patients, and detect EGFR gene mutations in paired samples.

Official Title
-----------------
Urinary Circulating Tumor DNA Detection in Non-small Cell Lung Cancer: a Prospective Study

Conditions
-----------------
Carcinoma, Non-small-cell Lung Cancer, Lung Neoplasms

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged 18 to 80 years Histologically confirmed diagnosis of stage non-small cell lung cancer undergoing surgical resection Completed and explicit information about TNM staging Paired specimens including tumor tissues, and both peripheral blood samples and urinary samples before and after surgery. Patients must have given written informed consent Exclusion Criteria: Unable to comply with the study procedure Malignant tumor history within the past 5 years Coexisting small cell lung cancer Unqualified tissue, blood or urine samples

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The concordant frequency of genomic results among tumor tissue DNA, urinary ctDNA and peripheral blood ctDNA. |  | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The difference of urine ctDNA detection effectiveness between different TNM stages NSCLC patients. |  | 18 months | 
| Correlation of urine ctDNA concentration preoperative,intraoperative and 3 days after surgery with clinical features and prognosis. |  | 18 months | 
| Lead time of tumor relapse detection by urine ctDNA than tumor markers and radiographic approaches. |  | 3 years | 
| Urinary ctDNA predictive value for locoregional recurrence and distant metastasis. |  | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Non-small-cell Lung Cancer, circulating tumor DNA, urine
Treatment of Keloidscars With Intralesional Triamcinolone and 5-fluorouracil Injections-prospective, Randomized, Controlled Trial - Pilot Study

Study Overview
=================
Brief Summary
-----------------
The aim of study is examine the efficacy of intralesional 5-fluorouracil injections in keloid disease treatment.

Official Title
-----------------
Treatment of Keloidscars With Intralesional Triamcinolone and 5-fluorouracil Injections-prospective, Randomized, Controlled Trial - Pilot Study

Conditions
-----------------
Keloidscars

Intervention / Treatment
-----------------
* Drug: 5-fluorouracil
* Drug: Triamcinolone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Person who has a keloidscar which could be treated with injection treatment Exclusion Criteria: Pregnancy, lactating, renal or liver failure

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Triamcinolone<br>kortikosteroid | Drug: 5-fluorouracil<br>* antimitotic drug<br>* Other names: Fluorouracil Accord;|
| Active Comparator: 5-fluorouracil<br>antimitotic drug | Drug: Triamcinolone<br> <br> * Other names: Lederspan;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Symptoms (pain, itching) of keloids and appearance of keloid | Change from baseline symptoms of scars baseline at one year with POSAS score | baseline and one year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Concentration change of hemoglobin and melanin | Camera analysis with spectrocutometry | 0 week, 3 week, 6 week, 12 week, 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Prospective, randomized controlled trial - pilot study
A Critical Appraisal of the Role of Near Infrared Spectroscopy (NIRS) in the Pediatric Intensive Care Unit (PICU)

Study Overview
=================
Brief Summary
-----------------
While near infrared spectroscopy is an exciting technology, scientific rigor is required in order to optimize its appropriate use in the clinical arena. This study will explore the feasibility and clinical applicability of data obtained from the NIRS device. The ability to noninvasively monitor peripheral perfusion remains an area of intense research. The most widely used method is pulse oximetry. The international mandate of its use in operating rooms in the early 1990s after the publication of the Harvard minimum standards for monitoring speaks to its unquestionable utility. Its pervasive application notwithstanding, pulse oximetry merely provides a calibrated ratio of arterial and venous hemoglobin saturation. While this data is valuable, time-tested, and even may hold the promise of accurately noninvasively trending cardiac output, cellular dysmetabolism -- hallmarks of vulnerable, yet viable tissue beds -- are beyond the predictive values of currently available devices.

Official Title
-----------------
Is There a Canary in the PICU? A Critical Appraisal of the Role of Near Infrared Spectroscopy (NIRS) in the Pediatric Intensive Care Unit (PICU)

Conditions
-----------------
Pediatric Intensive Care Unit

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: neonates to 16 year olds requiring stay in the PICU greater than 24 hours Exclusion Criteria: anticipated PICU stay less than 24 hours children with ALLOW NATURAL DEATH orders

Ages Eligible for Study
-----------------
Maximum Age: 15 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cardiac patients<br>Postoperative congenital heart disease patients requiring stay in the PICU | |
| non-cardiac patients<br>non-cardiac patients requiring stay in the PICU | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparison of data obtained using Near Infrared Spectroscopy (NIRS) versus traditional Pediatric Intensive Care Unit (PICU) clinical parameters | Upon arrival to PICU, 1 lead will be place on the forehead to monitor cerebral regional saturation (CrSO2)and 1 lead will be placed on the flank to measure somatic regional saturation (SrSO2). | 48 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
all children entering the PICU eligible for enrollment, age range: neonate to 16 years
Impact of Active and Healthy Families

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the impact of the 10-week Active and Healthy Families (AHF) intervention on body mass index (BMI) in Latino youth aged 5-12 years.

Official Title
-----------------
Impact of Active and Healthy Families (Familias Activas y Saludables): A Family-Based Group Medical Appointment Model for Childhood Obesity in Federally Qualified Health Centers

Conditions
-----------------
Overweight, Obesity

Intervention / Treatment
-----------------
* Behavioral: Active and Healthy Families


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged 5-12 years Body mass index greater than or equal to the 85th percentile for age and sex Patients seen at Contra Costa County clinics participating in Active and Healthy Families Spanish speaking Parent of participant Exclusion Criteria: Previous participation in Active and Healthy Families

Ages Eligible for Study
-----------------
Minimum Age: 5 Years
Maximum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Family group sessions<br>Active and Healthy Families | Behavioral: Active and Healthy Families<br>* Pediatric obesity intervention delivered through five bi-weekly Active and Healthy Families family-based group medical appointments (i.e., sessions).<br>|
| No Intervention: Wait-list control<br>Controls may participate in Active and Healthy Families after the study | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes from baseline in body mass index (BMI) | Change from baseline are assessed from measured height and weight | Baseline and at week 10 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline in blood glucose |  | Baseline and week 10 | 
| Changes from baseline in fasting lipids |  | Baseline and week 10 | 
| Change from baseline in insulin resistance |  | Baseline and week 10 | 
| Change from baseline in blood pressure |  | Baseline and week 10 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hispanic Americans, Family, Primary Health Care, Pediatrics, Obesity, Overweight, Clinical trial, Body mass index
Corneal Endothelium Delivery Instrument

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether the surgical outcomes in patients undergoing Descemet's Stripping Endothelial Keratoplasty (DSEK) are improved with the use of an insertion device over the traditional forceps insertion method.

Detailed Description
-----------------
Laboratory studies and clinical functionality tests have shown that the study device safely forms the tissue without creasing or folding. It allows the allograft tissue to safely pass into the anterior chamber without compression, crushing, or squeezing the endothelial cells. The device provides continuous irrigation into the eye to prevent collapse of the anterior chamber during insertion. Our study will focus on the safety and efficacy of the novel instrument over the current method of insertion (forceps). FDA has classified the device as Class I, Reserved.

Official Title
-----------------
Endothelial Graft Injector Versus Folding Forceps Insertion During Descemet's Stripping Endothelial Keratoplasty (DSEK)

Conditions
-----------------
Corneal Transplantation

Intervention / Treatment
-----------------
* Device: EndoSaver™ Corneal Endothelium Delivery Instrument


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with Fuchs endothelial dystrophy or bullous keratopathy determined to need a corneal transplant for visual restoration.

Ages Eligible for Study
-----------------
Minimum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: EndoSaver™ Corneal Endothelium Delivery Instrument|Efficacy of device to maintain function and integrity of corneal endothelial cells during insertion into the eye during keratoplasty.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 6-month post-operative endothelial cell density |  | 6-months post-operatively | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 12-month post-operative endothelial cell density |  | 12-months post-operatively | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
EK, Endothelial Keratoplasty, Descemet Stripping Endothelial Keratoplasty, Corneal Transplantation, Keratoplasty, DSEK, DSAEK
KvaliMed - a Quality Project With Focus on Patients in Antipsychotic Treatment

Study Overview
=================
Brief Summary
-----------------
Rating and registration in KMS database of all patients in anti-psychotic treatment with 8 selected items from PANSS, GAF, 21 selected items from UKU, 3 selected items from TSQM. and measurement of compliance. Frequency of use of rating scales per participating health care professional.

Official Title
-----------------
KvaliMed - a Quality Project With Focus on Patients in Antipsychotic Treatment

Conditions
-----------------
Antipsychotic Treatment, Quality Assurance, Medical Treatment

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients where a physician has decided to treat the patient with antipsychotics. All patients that are treated within the Danish health care system Exclusion Criteria: Patients that are treated in accordance with Law concerning freedom deprivation and other compulsion in psychiatry Patients that are in judicial measure
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| GAF score >= 30 or have an improvement on >= 5 points at the GAF scale |  | All measures are rated every ½ year at least.GAF: At least 85 % of the rated patients must have a score >= 30 or have an improvement on >= 5 points at the GAF scale | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PANSS: Share af patients that have a score >= 3 on each an every of the following items P1, P2, P3, N1, N4, N6, G5, G9 |  | PANSS: At least 70% of the patients have a score <= 3 on each an every of the following items P1, P2, P3, N1, N4, N6, G5, G9 | 
| UKU: Share of patients that have a score <=1 on the selected 21 items from the UKU scale |  | UKU: At least 75 % of the patients have a score on <=1 on the selected items UKU scale.At least 30 % of the patients are examined for metabolic syndrom. | 
| Compliance: Share of patients have according to the specialists evaluation have taken their antipsychotic medicine according to prescription |  | Compliance: At least 75% of the patients have according to the specialists evaluation taken their antipsychotic medicine according to prescription | 
| Patient satisfaction:Share of patients that scores in one of the to best categories i all selected 3 items in the TSQM scale. |  | Patient satisfaction:At least 65 % of the patients scores in one of the to best kategories in all the selected 3 items in the TSQM scale. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Quality assurance, medical treatment, Patient satisfaction
Optimal Timing for Repair of Left to Right Shunt Lesions

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the optimal timing for repair of left-to-right shunt lesions such as ventricular septal defects and atrioventricular canals.

Detailed Description
-----------------
In the past, children with left-to-right shunt lesions such as ventricular septal defects and atrioventricular canal defects were palliated with a pulmonary artery band. This prevented injury to the pulmonary vasculature while the child grew to a size where complete repair could be undertaken. With the improvements in surgical technique and critical care, there is a push to do a primary complete repair for these defects at younger and younger ages. These operations should be delayed as long as possible to allow for growth but not so long that there is unnecessary heart failure and medication requirements. The primary aim is to determine the optimal timing for repair of left-to-right shunt lesions such as ventricular septal defects and atrioventricular canals. The secondary aim is to define the criteria for failing medical anti-congestive heart failure therapy. This study will be conducted through a retrospective chart review.

Official Title
-----------------
Optimal Timing for Repair of Left-to-Right Shunt Lesions

Conditions
-----------------
Ventricular Septal Defects, Persistent Common Atrioventricular Canal

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients in the congenital surgery database Patients who have undergone repair of ventricular septal defects Patients who have undergone repair of atrioventricular canal defects
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pediatric health, cardiac, pediatric population, congenital heart surgery, left to right shunt lesions, heart surgery, Atrioventricular canal defects